Septic shock is a life-threatening condition in which there is infection everywhere in the human body. It occurs in 750,000 clients each year in the United States. Of these patients, more than half will succumb to the illness. In the United States, the yearly cost from it is more than $20.3 billion (1, 2, 3). This disease has several names such as bacteremic shock, septicemic shock, endotoxic shock, and warm shock (2).
This infirmity can occur in anyone; however, it mostly takes place in very young or very old clients. These age groups are likely to have weak immune systems. There has long been much in the medical literature which describes the benefit of glucocorticoid therapy in people who have this. However, this is not the usual approach for the management of individuals who have it. In fact, the usage of fluid is still the first-line method in most patients. Nevertheless, the employment of steroid therapy is effective in some clients especially when the other approaches are not beneficial (1, 2, 3). When there is a clinical indication for this, intravenous hydrocortisone is the recommendation (1).